These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 9582617

  • 1. Melatonin as a new possible anti-inflammatory agent.
    Lissoni P, Rovelli F, Meregalli S, Fumagalli L, Musco F, Brivio F, Brivio O, Esposti G.
    J Biol Regul Homeost Agents; 1997; 11(4):157-9. PubMed ID: 9582617
    [Abstract] [Full Text] [Related]

  • 2. Immunomodulatory properties of a pineal indole hormone other than melatonin, the 5-methoxytryptophol.
    Lissoni P, Pittalis S, Rovelli F, Zecchini S, Casati M, Tremolada M, Pelizzoni F.
    J Biol Regul Homeost Agents; 1996; 10(1):27-30. PubMed ID: 9049779
    [Abstract] [Full Text] [Related]

  • 3. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P, Tisi E, Brivio F, Ardizzoia A, Crispino S, Barni S, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P, Bolis S, Brivio F, Fumagalli L.
    Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
    [Abstract] [Full Text] [Related]

  • 5. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
    Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
    [Abstract] [Full Text] [Related]

  • 6. Is there a role for melatonin in supportive care?
    Lissoni P.
    Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
    [Abstract] [Full Text] [Related]

  • 7. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJ.
    J Biol Regul Homeost Agents; 1997 Mar; 11(3):119-22. PubMed ID: 9498162
    [Abstract] [Full Text] [Related]

  • 8. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P, Barni S, Ardizzoia A, Brivio F, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1992 Mar; 6(4):132-6. PubMed ID: 1296454
    [Abstract] [Full Text] [Related]

  • 9. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
    Lissoni P, Ardizzoia A, Tisi E, Rossini F, Barni S, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1993 Mar; 7(1):34-6. PubMed ID: 8346714
    [Abstract] [Full Text] [Related]

  • 10. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P, Brivio F, Viviani S, Fumagalli L.
    J Biol Regul Homeost Agents; 1999 Mar; 13(2):110-4. PubMed ID: 10503734
    [Abstract] [Full Text] [Related]

  • 11. Role of the pineal gland in the control of macrophage functions and its possible implication in cancer: a study of interactions between tumor necrosis factor-alpha and the pineal hormone melatonin.
    Lissoni P, Barni S, Tancini G, Brivio F, Tisi E, Zubelewicz B, Braczkowski R.
    J Biol Regul Homeost Agents; 1994 Mar; 8(4):126-9. PubMed ID: 7660855
    [Abstract] [Full Text] [Related]

  • 12. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F.
    Anticancer Res; 2008 Mar; 28(2B):1377-81. PubMed ID: 18505083
    [Abstract] [Full Text] [Related]

  • 13. Melatonin as biological response modifier in cancer patients.
    Neri B, de Leonardis V, Gemelli MT, di Loro F, Mottola A, Ponchietti R, Raugei A, Cini G.
    Anticancer Res; 1998 Mar; 18(2B):1329-32. PubMed ID: 9615811
    [Abstract] [Full Text] [Related]

  • 14. Biochemotherapy with immunomodulating pineal hormones other than melatonin: 5-methoxytryptamine as a new oncostatic pineal agent.
    Lissoni P.
    Pathol Biol (Paris); 2007 Mar; 55(3-4):198-200. PubMed ID: 17451889
    [Abstract] [Full Text] [Related]

  • 15. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F.
    J Biol Regul Homeost Agents; 1995 Mar; 9(1):31-3. PubMed ID: 8553906
    [Abstract] [Full Text] [Related]

  • 16. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
    Lissoni P, Rovelli F, Frassineti A, Fumagalli L, Malysheva O, Conti A, Maestroni G.
    Neuro Endocrinol Lett; 2000 Mar; 21(4):319-323. PubMed ID: 11455367
    [Abstract] [Full Text] [Related]

  • 17. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C, Conti A, Maestroni GJ.
    Anticancer Res; 1990 Mar; 10(6):1759-61. PubMed ID: 2285255
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of erythrosedimentation rate in cancer in relation to cytokine production: correlation with high IL-6 and low IL-2 blood concentrations.
    Lissoni P, Brivio F, Pittalis S, Rovelli F, Rescaldani R, Perego MS, Grassi MG, Barni S, Tancini G, Majorca F, Fumagalli L.
    J Biol Regul Homeost Agents; 1996 Mar; 10(2-3):60-2. PubMed ID: 9250887
    [Abstract] [Full Text] [Related]

  • 19. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, Tancini G, Characiejus D, Kothari L.
    J Biol Regul Homeost Agents; 1993 Mar; 7(4):121-5. PubMed ID: 8023699
    [Abstract] [Full Text] [Related]

  • 20. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
    Lissoni P, Barni S, Tancini G, Rovelli F, Ardizzoia A, Conti A, Maestroni GJ.
    Oncology; 1993 Mar; 50(6):399-402. PubMed ID: 8233281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.